Q1 Earnings Forecast for ALLO Issued By Zacks Research

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Analysts at Zacks Research issued their Q1 2027 earnings estimates for Allogene Therapeutics in a report issued on Wednesday, April 2nd. Zacks Research analyst R. Department expects that the company will post earnings of ($0.32) per share for the quarter. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Allogene Therapeutics’ FY2027 earnings at ($1.18) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.06.

A number of other research analysts also recently issued reports on ALLO. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Friday, March 14th. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 14th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a research note on Friday, March 14th. Finally, HC Wainwright decreased their target price on Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $9.29.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $1.44 on Friday. The stock has a market capitalization of $312.86 million, a price-to-earnings ratio of -0.92 and a beta of 0.99. Allogene Therapeutics has a 52-week low of $1.30 and a 52-week high of $4.25. The stock’s 50 day moving average price is $1.81 and its two-hundred day moving average price is $2.20.

Insider Activity at Allogene Therapeutics

In related news, EVP Zachary Roberts sold 27,199 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the sale, the executive vice president now directly owns 488,054 shares of the company’s stock, valued at approximately $868,736.12. This represents a 5.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction on Friday, March 14th. The stock was sold at an average price of $1.96, for a total transaction of $91,469.28. Following the transaction, the chief executive officer now directly owns 5,276,569 shares in the company, valued at $10,342,075.24. This represents a 0.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 104,866 shares of company stock valued at $194,461. 24.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Allogene Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its stake in Allogene Therapeutics by 1.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company’s stock valued at $1,361,000 after purchasing an additional 5,642 shares during the period. California State Teachers Retirement System boosted its holdings in shares of Allogene Therapeutics by 6.0% in the 4th quarter. California State Teachers Retirement System now owns 135,554 shares of the company’s stock worth $289,000 after buying an additional 7,685 shares during the last quarter. Invesco Ltd. grew its position in Allogene Therapeutics by 7.0% during the fourth quarter. Invesco Ltd. now owns 127,486 shares of the company’s stock valued at $272,000 after buying an additional 8,359 shares during the period. ProShare Advisors LLC increased its holdings in Allogene Therapeutics by 25.6% during the fourth quarter. ProShare Advisors LLC now owns 46,082 shares of the company’s stock worth $98,000 after buying an additional 9,388 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in Allogene Therapeutics by 2.1% in the fourth quarter. Nordea Investment Management AB now owns 460,641 shares of the company’s stock worth $986,000 after acquiring an additional 9,635 shares during the period. 83.63% of the stock is owned by institutional investors.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).